Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERBERT G MARKLEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1043251598
CMS profile
273519
Location
WORCESTER, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$27,398.05

214 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $10,820.31 49
Teva Pharmaceuticals USA, Inc. $7,783.44 68
Lilly USA, LLC $6,141.57 17
Amgen Inc. $1,347.31 22
Allergan, Inc. $557.71 17
Biohaven Pharmaceuticals, Inc. $404.00 24
Amneal Pharmaceuticals LLC $88.93 4
Lundbeck LLC $80.96 4
Supernus Pharmaceuticals, Inc. $60.70 3
Novartis Pharmaceuticals Corporation $57.47 3
Almatica Pharma LLC $38.34 2
PFIZER INC. $17.31 1

Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERBERT G MARKLEY

NPI 1043251598 · CMS profile ID 273519

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

WORCESTER, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043251598?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERBERT G MARKLEY, NPI 1043251598, CMS profile ID 273519. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043251598?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HERBERT G MARKLEY, NPI 1043251598, CMS profile ID 273519. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043251598?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HERBERT G MARKLEY, NPI 1043251598, CMS profile ID 273519, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043251598?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

214 matching records · $27,398.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 214 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 214.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $12.6109/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473353 CMS
AbbVie Inc. $12.6009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505081 CMS
Biohaven Pharmaceuticals, Inc. $29.1709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559137 CMS
Amneal Pharmaceuticals LLC $26.8709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667961 CMS
Teva Pharmaceuticals USA, Inc. $11.0309/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473349 CMS
Teva Pharmaceuticals USA, Inc. $3.4509/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473345 CMS
Allergan, Inc. $9.0609/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792864859 CMS
AbbVie Inc. $18.3508/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505075 CMS
Teva Pharmaceuticals USA, Inc. $11.0308/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473339 CMS
AbbVie Inc. $15.1608/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505069 CMS
Amgen Inc. $34.9908/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825353533 CMS
AbbVie Inc. $18.2808/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505063 CMS
Teva Pharmaceuticals USA, Inc. $11.0308/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473335 CMS
AbbVie Inc. $15.1608/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505057 CMS
Amgen Inc. $33.5908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825353529 CMS
Teva Pharmaceuticals USA, Inc. $2.4708/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473331 CMS
Biohaven Pharmaceuticals, Inc. $6.6608/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559135 CMS
Teva Pharmaceuticals USA, Inc. $11.5908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473323 CMS
Teva Pharmaceuticals USA, Inc. $34.2408/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473327 CMS
AbbVie Inc. $14.2208/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505051 CMS
Biohaven Pharmaceuticals, Inc. $9.3608/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559133 CMS
Lilly USA, LLC $23.7008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819172303 CMS
Teva Pharmaceuticals USA, Inc. $11.5908/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473319 CMS
AbbVie Inc. $15.9408/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505045 CMS
AbbVie Inc. $14.3208/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505039 CMS
Biohaven Pharmaceuticals, Inc. $3.7308/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559131 CMS
Lundbeck LLC $16.6708/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845921621 CMS
Teva Pharmaceuticals USA, Inc. $13.2408/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473315 CMS
Allergan, Inc. $5.8107/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792864857 CMS
Amgen Inc. $18.5907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825353525 CMS
Biohaven Pharmaceuticals, Inc. $30.7507/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559129 CMS
Teva Pharmaceuticals USA, Inc. $13.2407/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473311 CMS
AbbVie Inc. $2,400.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505033 CMS
Teva Pharmaceuticals USA, Inc. $2.3507/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473305 CMS
Teva Pharmaceuticals USA, Inc. $1.5607/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473297 CMS
Teva Pharmaceuticals USA, Inc. $13.2507/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473301 CMS
AbbVie Inc. $12.7807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505027 CMS
Allergan, Inc. $8.2407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792864855 CMS
Biohaven Pharmaceuticals, Inc. $3.9207/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559127 CMS
Lilly USA, LLC $1.0007/15/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819185565 CMS
Biohaven Pharmaceuticals, Inc. $7.4207/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559125 CMS
Teva Pharmaceuticals USA, Inc. $27.6507/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473293 CMS
Teva Pharmaceuticals USA, Inc. $13.2507/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473289 CMS
AbbVie Inc. $14.2207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505021 CMS
Almatica Pharma LLC $13.6007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208477 CMS
Teva Pharmaceuticals USA, Inc. $13.2407/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473285 CMS
Biohaven Pharmaceuticals, Inc. $5.2707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559123 CMS
AbbVie Inc. $22.1006/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795505015 CMS
Biohaven Pharmaceuticals, Inc. $5.5106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852559121 CMS
Teva Pharmaceuticals USA, Inc. $3.0806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839473281 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,239.13 200
PY2020 $54,393.49 204
PY2021 $27,398.05 214
PY2022 $30,680.89 179
PY2023 $8,249.47 145
PY2024 $8,862.10 141
PY2025 $7,276.94 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $8,975.50 18
PY2024 Principal investigator $1,172.21 2
PY2023 Principal investigator $1,899.00 2
PY2022 Recipient $297.00 1
PY2022 Principal investigator $4,544.00 5
PY2021 Recipient $5,801.50 2
PY2021 Principal investigator $56,471.34 12
PY2020 Recipient $761.85 2
PY2020 Principal investigator $38,576.33 12
PY2019 Principal investigator $53,064.77 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $6,450.00 09/24/2025 Non-covered Recipient Entity
NERHC Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228771101
Principal investigator 1 Ipsen Innovation $77.00 07/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287718
Principal investigator 1 Ipsen Innovation $77.00 07/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287720
Principal investigator 1 Ipsen Innovation $77.00 07/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287722
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287708
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287710
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287712
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287714
Principal investigator 1 Ipsen Innovation $68.90 04/28/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287716
Principal investigator 1 Ipsen Innovation $180.00 02/20/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287696
Principal investigator 1 Ipsen Innovation $300.00 02/20/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287698
Principal investigator 1 Ipsen Innovation $300.00 02/20/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287700
Principal investigator 1 Ipsen Innovation $150.00 02/18/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287702
Principal investigator 1 Ipsen Innovation $90.00 02/18/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287704
Principal investigator 1 Ipsen Innovation $150.00 02/18/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287706
Principal investigator 1 Ipsen Innovation $300.00 01/27/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287690
Principal investigator 1 Ipsen Innovation $180.00 01/27/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287692
Principal investigator 1 Ipsen Innovation $300.00 01/27/2025 Non-covered Recipient Entity
New England Regional Headache Center, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287694